Patients with a higher IPS value had a better response to PD-1 and CTLA-4 inhibitors, as the violin diagram showed that low-risk samples had higher IPS which suggested that HCC patients in the low-risk cohort could receive better immunotherapy efficacy (Figure 5(b)). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.